Skip to main content
OpenTrials
Completed

NCT Number: NCT01391325

Allopurinol Outcome Study

This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for each patient.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Camperdown, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meets the diagnosis of gout according to the American Rheumatism Association (ARA) Criteria for the Classification of Acute Arthritis of Primary Gout.
  • Not on a urate lowering therapy (ULT) must have an sUA level ≥ 8.0 mg/dL at screening.
  • If on concomitant ULT must have an sUA level ≥ 6.5 mg/dL at screening.
  • Must have had at least 2 gout flares in the past year.

Exclusion criteria

  • Consumption of more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
  • History or suspicion of drug abuse.
  • History of autoimmune disease requiring systemic treatment.
  • Known or suspected human immunodeficiency virus (HIV), hepatitis C antibody (HCV), or hepatitis B antibody (HBsAg) infection.
  • History of malignancy within the previous 5 years (with the exception of nonmelanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer).
  • Myocardial infarction, unstable angina, New York Heart Association (NYHA) class III or IV heart failure, or stroke within the last 12 months.
  • Uncontrolled hypertension (systolic pressure above 160 mm Hg or diastolic pressure above 95 mm Hg).
  • Estimated creatinine clearance < 30 mL/min by Cockcroft-Gault formula.
  • Kidney or other organ transplant.
  • Active peptic ulcer disease requiring treatment.
  • History of xanthinuria, active liver disease, or hepatic dysfunction.
  • If unable to take gout flare prophylaxis of either colchicine or nonsteroidal anti-inflammatory drugs (NSAIDs) due to contraindication (e.g. toxicity, renal function, use of contraindicated medications).
  • Known hypersensitivity or allergy to allopurinol.

Treatment and study plan

Allopurinol

Drug

Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.

Primary outcomes

  1. Safety of Allopurinol

    Time frame: Every month for 6 months.

    Proportion of subjects who experienced at least one Treatment Emergent Adverse Event (TEAE) during the study.

Secondary outcomes

  1. Proportion of Subjects With Serum Urate (sUA) Less Than 6.0 mg/dL

    Time frame: Month 6

    Proportion of subjects with serum urate (sUA) less than 6.0 mg/dL at Month 6 using Last Observation Carried Forward (LOCF) for subjects with missing values at Month 6.

  2. Incidence of Gout Flares

    Time frame: Every month for 6 months.

    Proportion of subjects who experienced at least one gout flare requiring treatment during the study.

  3. Mean Change From Baseline to Month 6 in SF-36 PCS+MCS

    Time frame: Month 6

    The SF-36 is a short-form health survey with 36 questions that yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical (PCS) and mental health (MCS) summary. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability. The component scores (PCS and MCS) are norm-based to a standard population with a mean of 50 and a standard deviation of 10.

Sponsors and collaborators

Lead sponsor

Ardea Biosciences, Inc.

Industry

Registry information

Official study title

Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)

Acronym: LASSO

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jul 12, 2011
Registry last updated
Jun 17, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.